IAN HERBERT: When Jurgen Klopp appeared in the media area after a Paris Paralympics badminton match this summer, you imagined some of the prickliness which had often characterised his discussions ...

Part C was structured as a double-blind, randomized, placebo-controlled trial, designed to assess the safety and tolerability of IMU-856 in patients with celiac disease during periods of gluten-free ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.